Wang Ming-Yao, Zhou Ting-Yue, Zhang Zhi-Dong, Liu Hao-Yang, Zheng Zhi-Yao, Xie Hui-Qi
Laboratory of Stem Cell and Tissue Engineering Orthopedic Research Institute Med-X Center for Materials State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu China.
MedComm (2020). 2021 Sep 2;2(3):351-380. doi: 10.1002/mco2.74. eCollection 2021 Sep.
Mesenchymal stromal/stem cells (MSCs) have a great potential to proliferate, undergo multi-directional differentiation, and exert immunoregulatory effects. There is already much enthusiasm for their therapeutic potentials for respiratory inflammatory diseases. Although the mechanism of MSCs-based therapy has been well explored, only a few articles have summarized the key advances in this field. We hereby provide a review over the latest progresses made on the MSCs-based therapies for four types of inflammatory respiratory diseases, including idiopathic pulmonary fibrosis, acute respiratory distress syndrome, chronic obstructive pulmonary disease, and asthma, and the uncovery of their underlying mechanisms from the perspective of biological characteristics and functions. Furthermore, we have also discussed the advantages and disadvantages of the MSCs-based therapies and prospects for their optimization.
间充质基质/干细胞(MSCs)具有巨大的增殖潜力、可进行多向分化并发挥免疫调节作用。人们对其在呼吸道炎症性疾病治疗中的潜力已充满热情。尽管基于MSCs的治疗机制已得到充分探索,但仅有少数文章总结了该领域的关键进展。在此,我们对基于MSCs的治疗在四种炎症性呼吸道疾病(包括特发性肺纤维化、急性呼吸窘迫综合征、慢性阻塞性肺疾病和哮喘)方面的最新进展以及从生物学特性和功能角度对其潜在机制的揭示进行综述。此外,我们还讨论了基于MSCs的治疗的优缺点及其优化前景。